Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 2/20 | 0.45 |
| ▸ | PLG | P00747 | 2/20 | 0.45 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 6/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778981 | 0.85 | ACE (0.53) | TSHRLTA4HACEACE2 | |
| SCHEMBL6778573 | 0.79 | ACE (0.60) | TSHRXIAPF2ACEACE2 | |
| SCHEMBL6777165 | 0.77 | ACE (0.64) | TSHRXIAPTACR1ACEACE2 | |
| SCHEMBL8655052 | 0.76 | LTA4H (0.59) | LTA4HACEACE2 | |
| SCHEMBL8655055 | 0.76 | LTA4H (0.59) | LTA4HACEACE2 | |
| SCHEMBL6438372 | 0.75 | ACE (0.58) | LTA4HACEACE2 | |
| SCHEMBL8378226 | 0.75 | ACE (0.58) | LTA4HACEACE2 | |
| SCHEMBL6438368 | 0.75 | ACE (0.58) | LTA4HACEACE2 | |
| SCHEMBL10403636 | 0.74 | LTA4H (0.57) | F10PLGST14F2PLAU | |
| SCHEMBL7321460 | 0.73 | ACE (0.77) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864249-B2 | Pharmaceutical compositions containing them are of the class of thrombin inhibitors which are useful as anticoagulants. | LG LIFE SCIENCES, LTD. (KR) | 2005-03-08 | — | — | US | disclosed |
| EP-1140918-B1 | THROMBIN INHIBITORS | LG LIFE SCIENCES LTD (KR) | 2004-08-11 | — | — | EP | disclosed |
| US-6774110-B2 | ANTITHROMBOTIC ACTIVITY AND HIGH ORAL BIOAVAILABILITY; E.G. N-AMINOSULFONYL-D-DIPHENYLALANYL-L-PROLYL-((4-AMIDINOPHENYL)METHYL)AMIDE | LG LIFE SCIENCES LTD. (KR) | 2004-08-10 | — | — | US | disclosed |
| US-20030134801-A1 | Pharmaceutical compositions containing them are of the class of thrombin inhibitors which are useful as anticoagulants. | LG LIFE SCIENCES, LTD. | 2003-07-17 | — | — | US | disclosed |
| US-6492402-B1 | ANTICOAGULANTS; PEPTIDE DERIVATIVES HAVING HIGH ANTITHROMBOTIC ACTIVITY AND ORAL BIOAVAILABILITY | LG LIFE SCIENCES, LTD. (KR) | 2002-12-10 | — | — | US | disclosed |
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | LG LIFE SCIENCES LTD. (KR) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | F2, SERPINC1, TFPI | TSHR 810/4885F10 65/4885PLG 34/4885 |
| US-20030134801-A1 | Pharmaceutical compositions containing them are of the class of thrombin inhibitors which are useful as anticoagulants. | SERPINC1, F2, F12 | TSHR 1877/4885F10 11/4885PLG 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.